Compare Manhattan Associates Inc (MANH) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Twist Bioscience Corp — how do they compare? Manhattan Associates Inc trades at $200.5 (market cap $11.23B), while Twist Bioscience Corp trades at $125.26 (market cap $7.86B). The key difference: Manhattan Associates Inc is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.
| MANH | TWST | |
|---|---|---|
Market Cap | $11.23B | $7.86B |
Sector | Technology | Health |
52-Week High | $219.33 | $125.21 |
52-Week Low | $120.88 | $24.16 |
Enterprise Value | $11.09B | $7.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $192.63, down 1.32% today, but remains near its consensus price target of $210.33. The stock shows strong fundamentals with a 96.38% ROE and consistent earnings beats in recent quarters, including Q2 2026 EPS of $1.39 versus $1.32 expected. Technical indicators are bullish overall, with moving averages signaling strength, though RSI levels show some divergence. Recent news highlights a legal investigation but also underscores strong cloud revenue growth and positive analyst sentiment.
The outlook for MANH is positive, driven by robust profitability and earnings momentum, offering potential upside to the price target. Key risks include the ongoing legal investigation into fiduciary duties and potential macroeconomic volatility affecting tech stocks. Investors should weigh strong fundamentals against these legal and market risks.
Twist Bioscience (TWST) trades at $125.16, up 1.66% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is strong, with Q3 2026 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights a $300 million public offering and expansion in AI-driven drug discovery, fueling investor optimism.
The outlook is mixed: robust revenue growth and analyst buy ratings (78.57%) support upside, but persistent losses, high valuations (P/S of 17.73), and cash flow deficits pose risks. Investors should weigh the potential for EBITDA breakeven by fiscal 2027 against execution challenges in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
